» Articles » PMID: 15522894

PG-M/versican Binds to P-selectin Glycoprotein Ligand-1 and Mediates Leukocyte Aggregation

Overview
Journal J Cell Sci
Specialty Cell Biology
Date 2004 Nov 4
PMID 15522894
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

P-selectin glycoprotein ligand-1 (PSGL-1), a glycoprotein expressed on the cell surface of leukocytes, binds to selectins and mediates leukocyte rolling on the vascular endothelium. Here we report that PSGL-1 binds to the C-terminal (G3 domain) of the extracellular proteoglycan PG-M/versican. Cells transfected with PSGL-1 or a shorter form containing the binding site, or cells expressing endogenous PSGL-1 aggregate in the presence of versican or G3 product. The aggregation appears to be induced by G3 multimers that bind to PSGL-1 and form a network. Endogenous versican and/or G3-containing fragments also bind to PSGL-1 in human plasma. Removal of the endogenous G3-containing fragments reduces the effect of plasma on leukocyte aggregation. Finally, the roles of G3-containing fragments in leukocyte aggregation were confirmed in a mouse model. Taken together, our results strongly support a physiologically relevant role for PSGL-1/versican binding and may have implications in the immunoresponse.

Citing Articles

Expression of Versican in the Retina and Its Implication in Retinal Disease.

Dillinger A, Hoffmann A, Tamm E Adv Exp Med Biol. 2025; 1468:423-427.

PMID: 39930232 DOI: 10.1007/978-3-031-76550-6_69.


Soluble Proteoglycans and Proteoglycan Fragments as Biomarkers of Pathological Extracellular Matrix Remodeling.

Kemberi M, Minns A, Santamaria S Proteoglycan Res. 2024; 2(4):e70011.

PMID: 39600538 PMC: 11587194. DOI: 10.1002/pgr2.70011.


Modulation of Extracellular Matrix Composition and Chronic Inflammation with Pirfenidone Promotes Scar Reduction in Retinal Wound Repair.

Jahnke L, Perrenoud V, Zandi S, Li Y, Conedera F, Enzmann V Cells. 2024; 13(2).

PMID: 38247855 PMC: 10814251. DOI: 10.3390/cells13020164.


V3: an enigmatic isoform of the proteoglycan versican.

Wight T, Day A, Kang I, Harten I, Kaber G, Briggs D Am J Physiol Cell Physiol. 2023; 325(2):C519-C537.

PMID: 37399500 PMC: 10511178. DOI: 10.1152/ajpcell.00059.2023.


Matrix proteoglycans in tumor inflammation and immunity.

Deb G, Cicala A, Papadas A, Asimakopoulos F Am J Physiol Cell Physiol. 2022; 323(3):C678-C693.

PMID: 35876288 PMC: 9448345. DOI: 10.1152/ajpcell.00023.2022.